Paraoxonase and arylesterase levels in autoimmune thyroid diseases

Figures & data

Table 1 Demographic and laboratory parameters of HT, GD, and healthy control groups

	GD	HT	Healthy controls	P
Age (year)	44.00 ± 14.36	41.44 ± 9.53	43.92 ± 12.78	0.811
Gender (F/M)	17/8	16/11	16/9	0.806
BMI (kg/m^2)	25.59 ± 3.06	26.64 ± 2.16	25.78 ± 2.01	0.375
FBG (mg/dl)	87.72 ± 6.47	86.96 ± 6.47	88.92 ± 8.15	0.760
Total-C (mg/dl)	175.00 ± 30.44	179.04 ± 30.53	173.48 ± 28.64	0.889
HDL-C (mg/dl)	47.92 ± 6.71	47.68 ± 6.59	46.74 ± 6.34	0.558
LDL-C (mg/dl)	112.44 ± 22.64	116.04 ± 29.26	105.25 ± 25.30	0.354
TG (mg/dl)	130.00 ± 29.32	129.80 ± 26.94	137.85 ± 46.26	0.624
Free T3 (pg/ml)	2.54 ± 0.38	2.82 ± 0.52	2.69 ± 0.48	0.075
Free T4 (ng/dl)	1.14 ± 0.23	1.08 ± 0.17	1.06 ± 0.14	0.189
TSH (uIU/ml)	2.15 ± 0.52	2.05 ± 0.99	2.29 ± 0.59	0.541
PON1 (U/ml)*	106.32 ± 14.38^a	92.15 ± 28.75^b	125.45 ± 26.18	<0.001
Salt-stimulated PON (U/ml)*	175.05 ± 102.27	161.23 ± 116.93	215.76 ± 93.76	0.035
ARE (U/ml)*	101.09 ± 48.51	109.47 ± 25.49	102.07 ± 34.69	0.241
LOOH (mol H2O2 equiv./l)*	11.30 ± 4.88^a^,^c	13.11 ± 4.07^b	5.98 ± 3.08	<0.001
–SH (mmol/l)*	0.16 ± 0.05^a	0.18 ± 0.09^b	0.45 ± 0.12	<0.001

Data were expressed as mean ± SS and *median (IQR). P < 0.005 was regarded as statistically significant. Graves’ disease, GD; Hashimoto thyoriditis, HT; body mass index, BMI; fasting blood glucose, FBG; high-density lipoprotein-cholesterol, HDL-C; low-density lipoprotein-cholesterol, LDL-C; triglyceride, TG; triiodothyronine, T3; tetraiodothyronine, T4; thyroid stimulating hormone, TSH; lipid hydroperoxide, LOOH; paraoxonase-1, PON1; arylesterase, ARE; total free sulfhydryl, –SH.

^aP<0.001 GD versus healthy control.

^bP<0.001 HT versus healthy control.

^cP<0.01 GD versus HT.

Figure 1 Correlation between serum basal PON1 and LOOH levels.

Figure 2 Correlation between serum basal PON1 levels and –SH.